DRonabinol 治疗 OSA (DROSA)
用屈大麻酚靶向治疗阻塞性睡眠呼吸暂停:概念验证和 II 期临床试验
This is an open-label trial that tests the effectiveness of Dronabinol in treating obstructive sleep apnea (OSA). All participants will take oral Dronabinol for two weeks. Sleep studies will be conducted before and after treatment to measure OSA severity.
研究概览
详细说明
Obstructive sleep apnea (OSA), is a serious respiratory disorder that involves repetitive cessation of breathing during sleep. It is estimated that 15-20 million people in the United States suffer from OSAS, which has been linked to increased risk for hypertension, heart failure, depression, and diabetes. The current standard of care for OSA, positive airway pressure (PAP), involves a mechanical device with low patient tolerance and adherence. Upper airway surgical approaches are also an option but are invasive and often unsuccessful. Effective drug treatments for OSA remain to be identified.
This study will enroll up to 120 Veterans so that 45 Veterans may complete the two-week open-label Dronabinol treatment trials. The results of the study will be used to develop a prediction model for OSA severity reduction after 2-week Dronabinol treatment vs. pretreatment AHI. Participants clinical (age, sex, body mass index, comorbidity) and pretreatment polysomnographic characteristics (sleep architecture, respiratory disturbance, and endotypes; loop-gain, arousal threshold, upper airway collapsibility and compensation) will be used to develop a prediction model for improvement of OSA with Dronabinol treatment. This prediction model will be used for a randomized clinical trial after the completion of this trial.
研究类型
注册 (估计的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习联系方式
- 姓名:Karen M Lenehan
- 电话号码:(312) 569-6343
- 邮箱:Karen.Lenehan@va.gov
研究联系人备份
- 姓名:Bharati Prasad, MD
- 电话号码:(312) 996-8433
- 邮箱:bharati.prasad@va.gov
学习地点
-
-
Illinois
-
Chicago、Illinois、美国、60612
- 招聘中
- Jesse Brown VA Medical Center, Chicago, IL
-
接触:
- Howard S Gordon, MD BS
- 电话号码:(312) 569-7331
- 邮箱:howard.gordon2@va.gov
-
接触:
- Karen M Lenehan
- 电话号码:(312) 569-6343
- 邮箱:Karen.Lenehan@va.gov
-
首席研究员:
- Bharati Prasad, MD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
1. AHI 15-50 per hour on pre-treatment polysomnography
Exclusion Criteria:
-
Positive Airway Pressure (PAP) treatment of obstructive sleep apnea (OSA): use > 4 hours per day for 30% of days within 3 months of enrollment. PAP use will be determined from device download data
-
Hypoglossal nerve stimulator (HNS) or oral appliance device treatment with use > 4 hours per day for 30% of days within 3 months of enrollment. HNS use will be determined by device download and oral appliance use by self-report
-
History of upper airway surgery for OSA (except adenotonsillectomy)
-
Central or mixed apneas >25% of respiratory events on diagnostic polysomnography
-
Arterial oxygen saturation < 75% for > 5% sleep time on pretreatment polysomnography
-
Body mass index > 45 kilograms per square meter (kg/m2)
-
If post-bariatric surgery, weight must be stable ±5% (per electronic medical records) for at least 6 months before the first dose of the study drug
-
Active enrollment in a weight loss program
-
Shiftwork within 3 months of enrollment
-
High-risk occupation: commercial driver and pilot
-
Motor vehicle accident or near-miss incident within 1 year of enrollment
-
Current drug or habitual alcohol use or positive urine drug screen
-
Comorbid medical and psychiatric disorders:
- Primary sleep disorders: e.g., narcolepsy, restless legs syndrome
- Uncontrolled mood disorder or a diagnosis of schizophrenia
- Initiation of new antidepressant or antipsychotic medication within 3 months
- Identified as high-risk for suicide in electronic health records
- Uncontrolled medical disorders (coronary heart disease, arrhythmia, congestive heart failure, chronic obstructive pulmonary disease, chronic hypoxemic or hypercapnic respiratory failure, stroke within 6 months of enrollment, chronic liver or kidney disease, autoimmune disorders)
-
Use of sedative-hypnotic medications within 30 days of enrollment
-
Complete blood count or liver function test values more than 1.5 times the upper limit of normal
-
Pregnancy
-
Allergy to cannabinoids or sesame oil
-
Average weekly alcohol consumption of more than 10 servings
-
Participation in other investigational protocols within 30 days of enrollment
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Single group
Open label Dronabinol treatment for two weeks. |
Open label Dronabinol treatment for two weeks.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Apnea Hypopnea Index (AHI)
大体时间:2 weeks
|
The change in AHI after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms. |
2 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
T<90
大体时间:2 weeks
|
The change in time below 90% oxygen saturation (T<90) after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms. |
2 weeks
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Psychomotor Vigilance Test (PVT)
大体时间:2 weeks
|
The change in Lapses on Psychomotor Vigilance Test (PVT) after two weeks of Dronabinol treatment will be determined from before and after treatment PVT using a 10 minute protocol. |
2 weeks
|
|
24-hour Mean Arterial Blood Pressure (BP)
大体时间:2 weeks
|
The change in 24- hour mean arterial blood pressure after two weeks of Dronabinol treatment will be determined from before and after treatment 24-hiur ambulatory BP recording. |
2 weeks
|
|
Sleep Efficiency
大体时间:2 weeks
|
The change in sleep efficiency after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms. |
2 weeks
|
|
Rapid Eye Movement (REM) Sleep
大体时间:2 weeks
|
The change in REM sleep after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms. |
2 weeks
|
|
Slow Wave Sleep
大体时间:2 weeks
|
The change in slow wave sleep after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms. |
2 weeks
|
|
Treatment Satisfaction Questionnaire for Medication (TSQM)
大体时间:2 weeks
|
Patient reported treatment satisfaction. TSQM scores have a range of 0 to 100, with higher scores indicating higher satisfaction. |
2 weeks
|
|
Epworth Sleepiness Scale (ESS)
大体时间:2 weeks
|
The change in Epworth Sleepiness Scale (ESS) will be measured after two weeks of Dronabinol treatment. ESS scores have a range of 0 to 24, with higher scores indicating greater sleepiness. |
2 weeks
|
|
Functional Outcomes of Sleep Questionnaire (FOSQ)
大体时间:2 weeks
|
The change in Functional Outcomes of Sleep Questionnaire (FOSQ) will be measured after two weeks of Dronabinol treatment. FOSQ score ranges from 5-20, with higher scores indicating better functional status. |
2 weeks
|
|
Pittsburgh Sleep Quality Index (PSQI)
大体时间:2 weeks
|
The change in Pittsburgh Sleep Quality Index (PSQI) will be measured after two weeks of Dronabinol treatment. The PSQI score ranges from 0 to 21. Higher scores indicate poorer sleep quality. |
2 weeks
|
|
Insomnia Severity Index (ISI)
大体时间:2 weeks
|
The change in Insomnia Severity Index (ISI) will be measured after two weeks of Dronabinol treatment. ISI ranges from 0 to 28, with higher scores indicating greater sleep disturbance. |
2 weeks
|
|
Post-Traumatic Stress Disorder; PTSD checklist (PCL-5)
大体时间:2 weeks
|
The change in Post-Traumatic Stress Disorder; PTSD checklist (PCL-5) will be measured after two weeks of Dronabinol treatment. PCL-5 scores range from 0 to 80, with higher scores indicating greater PTSD symptom severity. |
2 weeks
|
合作者和调查者
调查人员
- 首席研究员:Bharati Prasad, MD、Jesse Brown VA Medical Center, Chicago, IL
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.